Stacey Poloskey

839 total citations · 2 hit papers
17 papers, 565 citations indexed

About

Stacey Poloskey is a scholar working on Hematology, Molecular Biology and Neurology. According to data from OpenAlex, Stacey Poloskey has authored 17 papers receiving a total of 565 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 3 papers in Molecular Biology and 3 papers in Neurology. Recurrent topics in Stacey Poloskey's work include Hemophilia Treatment and Research (10 papers), Blood Coagulation and Thrombosis Mechanisms (6 papers) and Platelet Disorders and Treatments (3 papers). Stacey Poloskey is often cited by papers focused on Hemophilia Treatment and Research (10 papers), Blood Coagulation and Thrombosis Mechanisms (6 papers) and Platelet Disorders and Treatments (3 papers). Stacey Poloskey collaborates with scholars based in United States, France and United Kingdom. Stacey Poloskey's co-authors include Barbara A. Konkle, Louise C. Parr‐Brownlie, Debra A. Bergstrom, Roshni Kulkarni, Judith R. Walters, Kara Rice, Craig C Benson, Annemieke Willemze, Elaine F. Dannefer and Caitlin W. Hicks and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Stacey Poloskey

17 papers receiving 552 citations

Hit Papers

Efanesoctocog Alfa Prophylaxis for Patients with Severe H... 2023 2026 2024 2025 2023 2023 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A
    2023 100 citations Annette von Drygalski, Pratima Chowdary et al. New England Journal of Medicine profile →
  2. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
    2023 67 citations Guy Young, Alok Srivastava et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stacey Poloskey United States 13 326 115 67 62 58 17 565
Howard Weiner United States 8 136 0.4× 95 0.8× 57 0.9× 54 0.9× 50 0.9× 15 409
Annalisa Andreoli France 12 154 0.5× 71 0.6× 109 1.6× 23 0.4× 38 0.7× 17 376
Matthew Devine Australia 8 243 0.7× 139 1.2× 274 4.1× 27 0.4× 29 0.5× 15 535
Elena Vassallo Italy 8 95 0.3× 141 1.2× 273 4.1× 60 1.0× 62 1.1× 17 487
Sandra Goss United States 10 194 0.6× 75 0.7× 66 1.0× 30 0.5× 20 0.3× 16 453
D. Grab Germany 12 89 0.3× 52 0.5× 37 0.6× 60 1.0× 54 0.9× 26 418
Pradeep Krishnan Canada 12 89 0.3× 75 0.7× 39 0.6× 31 0.5× 13 0.2× 48 396
Gottardo De Angelis Italy 9 235 0.7× 36 0.3× 49 0.7× 27 0.4× 19 0.3× 19 414
K. Kapinas Greece 6 190 0.6× 68 0.6× 52 0.8× 25 0.4× 8 0.1× 9 546
Vana Tsimourtou Greece 12 98 0.3× 49 0.4× 29 0.4× 27 0.4× 25 0.4× 20 475

Countries citing papers authored by Stacey Poloskey

Since Specialization
Citations

This map shows the geographic impact of Stacey Poloskey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacey Poloskey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacey Poloskey more than expected).

Fields of papers citing papers by Stacey Poloskey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacey Poloskey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacey Poloskey. The network helps show where Stacey Poloskey may publish in the future.

Co-authorship network of co-authors of Stacey Poloskey

This figure shows the co-authorship network connecting the top 25 collaborators of Stacey Poloskey. A scholar is included among the top collaborators of Stacey Poloskey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacey Poloskey. Stacey Poloskey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Young, Guy, Alok Srivastava, Kaan Kavaklı, et al.. (2023). Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. The Lancet. 401(10386). 1427–1437. 67 indexed citations breakdown →
2.
Srivastava, Alok, Savita Rangarajan, Kaan Kavaklı, et al.. (2023). Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology. 10(5). e322–e332. 51 indexed citations
3.
Drygalski, Annette von, Pratima Chowdary, Roshni Kulkarni, et al.. (2023). Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. New England Journal of Medicine. 388(4). 310–318. 100 indexed citations breakdown →
4.
5.
Willemze, Annemieke, et al.. (2021). Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Advances. 6(4). 1089–1094. 29 indexed citations
6.
Négrier, Claude, MV Ragni, Inga Hegemann, et al.. (2021). Long-term Efficacy and Safety of Fitusiran in Participants with Hemophilia A and B: An Interim Analysis of the Phase 1/2 Open-Label Extension Study. Hämostaseologie. 1 indexed citations
7.
Young, Guy, Alok Srivastava, Kaan Kavaklı, et al.. (2021). Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI). Blood. 138(Supplement 1). 4–4. 12 indexed citations
8.
Pipe, Steven W., John Pasi, Toshko Lissitchkov, et al.. (2020). Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study. Blood. 136(Supplement 1). 3–4. 7 indexed citations
9.
Konkle, Barbara A., Amy D. Shapiro, Doris Quon, et al.. (2020). BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. New England Journal of Medicine. 383(11). 1018–1027. 95 indexed citations
10.
Konkle, Barbara A., Amy D. Shapiro, Doris Quon, et al.. (2018). BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer. Blood. 132(Supplement 1). 636–636. 13 indexed citations
11.
Poloskey, Stacey, Jeffrey W. Olin, James B. Froehlich, et al.. (2012). PHYSICAL EXAMINATION FINDINGS IN FIBROMUSCULAR DYSPLASIA: A REPORT OF THE UNITED STATES REGISTRY FOR FIBROMUSCULAR DYSPLASIA. Journal of the American College of Cardiology. 59(13). E2075–E2075. 2 indexed citations
12.
Sisk, Bryan A., et al.. (2012). Student perspectives on assessment: Experience in a competency-based portfolio system. Medical Teacher. 34(3). 221–225. 48 indexed citations
13.
Poloskey, Stacey, Jeffrey W. Olin, Pamela Mace, & Heather L. Gornik. (2012). Fibromuscular Dysplasia. Circulation. 125(18). e636–9. 22 indexed citations
14.
Poloskey, Stacey, Esther Kim, Patricia Arscott, et al.. (2012). Low yield of genetic testing for known vascular connective tissue disorders in patients with fibromuscular dysplasia. Vascular Medicine. 17(6). 371–378. 37 indexed citations
15.
Parr‐Brownlie, Louise C., Stacey Poloskey, Debra A. Bergstrom, & Judith R. Walters. (2009). Parafascicular thalamic nucleus activity in a rat model of Parkinson's disease. Experimental Neurology. 217(2). 269–281. 36 indexed citations
16.
Poloskey, Stacey, et al.. (2008). Cell proliferation in the striatum during postnatal development: preferential distribution in subregions of the ventral striatum. Brain Structure and Function. 213(1-2). 119–127. 6 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Howard Weiner Breakdown of academic impact, for papers by Annalisa Andreoli Breakdown of academic impact, for papers by Matthew Devine Breakdown of academic impact, for papers by Elena Vassallo Breakdown of academic impact, for papers by Sandra Goss Breakdown of academic impact, for papers by D. Grab Breakdown of academic impact, for papers by Pradeep Krishnan Breakdown of academic impact, for papers by Gottardo De Angelis Breakdown of academic impact, for papers by K. Kapinas Breakdown of academic impact, for papers by Vana Tsimourtou
Rankless by CCL
2026